Nonetheless, studies have observed a correlation between CHI3L1 levels and NfL levels in the CSF, which were stronger in RRMS patients compared to SPMS and primary progressive MS (PPMS), further contributing to the debate about whether CHI3L1 is a suitable biomarker for progressive MS [198]. The gene discussed is NEFL; the disease is myeloid sarcoma.